6 TECH OUTLOOKFebruary - 2020EditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comThe manufacturing of drugs is one of the key revenue-generating segments in the pharmaceutical industry, and the market holds enormous potential. With the growing demand for generic medicines and biologics, the capital-intensive nature of the business, and the complex manufacturing requirements, many pharmaceutical companies have identified the potential profitability in contracting with contract manufacturing organizations (CMOs) for both clinical and commercial stage manufacturing. Pharmaceutical and biotechnology companies continue to outsource to CMOs as a way to meet their fill-and-finish needs and reduce risk.In such a scenario, technology plays a vital role in boosting economies, enhance productivity, and the entire proficiencies for CMOs. AI is empowering CMOs to make sense of massive amounts of data, better understand their markets and customers, generate better leads, optimize their campaigns, and streamline operations. With improvements in security and cost, CMOs are adopting cloud computing and storage in force. The demand for API manufacturing has witnessed a sustained rise in the past few years, and it is expected to continue growing steadily, with further patent expiries expected in the future and a subsequent increase in global generic production capacities.CMOs have begun offering early development support to their customers, along with fully integrated services, which include specialized services like aseptic fill-finish. The increasing pressure to reduce manufacturing costs and expand competencies, such as marketing and research & development, are among the other essential factors to trigger the `virtual pharma' trend. As the big pharma companies continue to scale down on manufacturing, more significant opportunities for the CMOs are expected. This edition brings you some of the most prominent organizations that specialize in contract manufacturing space, the innovative solution they offer, and the promise they hold.Let us know your thoughts!Better Drug Development via DigitalizationCopyright © 2020 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.FEBRUARY - 20 - 2020, Vol 06 - Issue 02 (ISSN 2644-2787) Published by ValleyMedia Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405Albert RozarioTECH OUTLOOKTECH OUTLOOK
< Page 5 | Page 7 >